533884-09-2

Basic information

• Product Name: Erteberel (LY500307)
• Synonyms: LY500307;(3aS,4R,9bR)-1,2,3,3a,4,9b-Hexahydro-4-(4-hydroxyphenyl)cyclopenta[c][1]benzopyran-8-ol;Erteberel;LY500307 (Erteberel);(3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol;Erteberel (LY500307);Phenchlobenpyrrone
• CAS NO: 533884-09-2
• Molecular Formula: C18H18O3
• Molecular Weight: 282.33372
• Product Categories: Inhibitors
• Mol File: 533884-09-2.mol

Chemical Properties

• Boiling Point: 485.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.268
• Solubility: insoluble in H2O; ≥14.1 mg/mL in DMSO; ≥48.3 mg/mL in EtOH
• PKA: 9.79±0.30(Predicted)
• CAS DataBase Reference: Erteberel (LY500307)(CAS DataBase Reference)
• NIST Chemistry Reference: Erteberel (LY500307)(533884-09-2)
• EPA Substance Registry System: Erteberel (LY500307)(533884-09-2)

Safety Data

• Hazardous Substances Data: 533884-09-2(Hazardous Substances Data)

Usage

Uses

Erteberel is a highly selective estrogen receptor β (ERβ) agonist.

Biological Activity

erteberel (ly500307) is a potent and selective erβ (estrogen receptor beta) agonist (ec50 = 0.66 nm). [1]estrogen receptors are nuclear hormone receptors that act as a ligand-activated transcription factor. it regulates gene expression, cell proliferation and differentiation in target tissues and involved in breast cancer, endometrial cancer and osteoporosis etc. [1]in transcription assay of cotransfected human prostate cancer cell line, erteberel showed potency (ec50 = 0.66 nm), selectivity (32-fold) and full agonist function (>90% relative efficacy) to erβ than to erα. [1]in mouse model, prostate wet weight of cd-1 mice were measured following oral daily doses of erteberel for 7 days. results showed reduction on prostate weight in a dose-dependent manner (0.01 mg/kg – 0.05 mg/kg), and no effect on testes/seminal vesicle weight and androgens testosterone/dihydrotestosterone circulating level. [1]

references

[1] norman bh, dodge ja, richardson ti, borromeo ps, lugar cw, jones sa, chen k, wang y, durst gl, barr rj, montrose-rafizadeh c, osborne he, amos rm, guo s, boodhoo a, krishnan v. benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. j med chem. 2006 oct 19;49(21):6155-7.

Upstream product

• 928-90-5 5-hexyl-1-ol 
• 133430-99-6 4-(tert-butyldimethylsilyloxy)iodobenzene 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 65832-21-5 methyl 2-(trifluoromethylsulfonyloxy)cyclopent-1-enecarboxylate 
• 533884-39-8 2-(2,5-bis-methoxymethoxyphenyl)cyclopent-1-enecarboxylic acid methyl ester 
• 123-31-9 hydroquinone 
• 120186-59-6 (4-(benzyloxy)phenyl)magnesium bromide 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 1357444-51-9 (4-(benzyloxy)phenyl)((1S,2R)-2-(2,5-bis(benzyloxy)phenyl)cyclopentyl)methanone 
• 1357444-50-8 (4-(benzyloxy)phenyl)(2-(2,5-bis(benzyloxy)phenyl)cyclopent-1-en-1-yl)methanone 
• 1379614-64-8 2-(2,5-bis(benzyloxy)phenyl)cyclopent-1-enecarboxylic acid 
• 1266452-53-2 8-(benzyloxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one 

Relevant articles and documents

Acid-Promoted Cascade Cyclization to Produce 2-(4′-Alkoxyaryl)-3,4-Fused Tricyclic Dihydrobenzopyrans via a Vinylidene para-Quinone Methide Intermediate

We developed a novel method for synthesizing 2-(4-hydroxyaryl)-3,4-fused tricyclic dihydrobenzopyrans with 2,3-syn and 3,4-syn motif based on the acid-promoted cascade cyclization via vinylidene para-quinone methide intermediates. Using easily prepared li

Rhodium-catalyzed and zinc(II)-triflate-promoted asymmetric hydrogenation of tetrasubstituted α,β-unsaturated ketones

The asymmetric hydrogenation of tetrasubstituted α,β-unsaturated ketones has been accomplished using an in situ formed rhodium-Josiphos catalyst. The reaction is enhanced by addition of catalytic zinc(II) triflate, which significantly improves turnover fr

Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 2: Structure-activity relationship studies on the benzopyran scaffold

Benzopyrans are selective estrogen receptor (ER) β agonists (SERBAs), which bind the ER subtypes α and β in opposite orientations. Here we describe structure-activity relationship studies that led to the discovery of bezopyran 5b. X-ray crystal structures

Benzopyrans are selective estrogen receptor β agonists with novel activity in models of benign prostatic hyperplasia

Benzopyran selective estrogen receptor beta agonist-1 (SERBA-1) shows potent, selective binding and agonist function in estrogen receptor β (ERβ) in vitro assays. X-ray crystal structures of SERBA-1 in ERα and β help explain observed β-selectivity of this